HC Wainwright Has Optimistic View of OPKO Health Q2 Earnings

OPKO Health, Inc. (NASDAQ:OPK) – Stock analysts at HC Wainwright raised their Q2 2025 EPS estimates for shares of OPKO Health in a research report issued to clients and investors on Wednesday, March 12th. HC Wainwright analyst Y. Chen now expects that the biotechnology company will post earnings per share of ($0.07) for the quarter, up from their previous forecast of ($0.08). HC Wainwright has a “Buy” rating and a $3.00 price objective on the stock. The consensus estimate for OPKO Health’s current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for OPKO Health’s FY2025 earnings at ($0.30) EPS.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.08) by $0.09. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The firm had revenue of $183.60 million during the quarter, compared to the consensus estimate of $155.42 million.

OPK has been the subject of a number of other reports. Barrington Research reaffirmed an “outperform” rating and set a $2.25 price objective on shares of OPKO Health in a report on Wednesday, March 12th. StockNews.com raised shares of OPKO Health from a “sell” rating to a “hold” rating in a report on Monday, March 3rd.

OPKO Health Stock Up 4.0 %

Shares of NASDAQ:OPK opened at $1.81 on Monday. The firm has a fifty day moving average price of $1.63 and a two-hundred day moving average price of $1.57. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. OPKO Health has a one year low of $0.86 and a one year high of $2.04. The company has a market cap of $1.22 billion, a price-to-earnings ratio of -9.53 and a beta of 1.70.

Institutional Trading of OPKO Health

Several institutional investors have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in OPKO Health by 4.5% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 186,783 shares of the biotechnology company’s stock valued at $275,000 after buying an additional 8,064 shares during the period. Two Sigma Advisers LP raised its stake in shares of OPKO Health by 2.3% during the fourth quarter. Two Sigma Advisers LP now owns 381,197 shares of the biotechnology company’s stock valued at $560,000 after acquiring an additional 8,396 shares during the last quarter. FMR LLC raised its stake in shares of OPKO Health by 103.6% during the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 11,089 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its stake in shares of OPKO Health by 75.3% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company’s stock valued at $42,000 after acquiring an additional 12,417 shares during the last quarter. Finally, Comerica Bank raised its stake in shares of OPKO Health by 18.2% during the fourth quarter. Comerica Bank now owns 106,369 shares of the biotechnology company’s stock valued at $156,000 after acquiring an additional 16,369 shares during the last quarter. 64.63% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost purchased 500,000 shares of the business’s stock in a transaction on Wednesday, January 15th. The stock was acquired at an average cost of $1.48 per share, for a total transaction of $740,000.00. Following the completion of the transaction, the chief executive officer now directly owns 213,036,477 shares in the company, valued at approximately $315,293,985.96. This represents a 0.24 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In the last ninety days, insiders purchased 964,971 shares of company stock valued at $1,493,692. Insiders own 47.26% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.